Researchers find potential new therapeutic target for treating non-small cell lung cancer

Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.

The study appeared in the Feb. 13 online issue of Oncogene.

The IKBKE gene is part of a family of enzyme complexes involved in increasing cellular inflammation. IKBKE overexpression has been associated with breast and . However, it had not been linked to environmental carcinogen, such as , until now.

Tobacco smoke is the strongest documented initiator and promoter of lung cancer. The traditional model holds that tobacco components promote carcinogenesis through a process that leads to .

Recent studies have shown that tobacco smoke can also promote lung cancer through changes in the pathways that regulate and survival. This study explored identifying and understanding one of the signaling pathways in order to find potential to treat non-small cell lung cancer.

In this study, IKBKE was found to be induced by two : nicotine and a nicotine-derived nitrosamine ketone found in tobacco smoke. Their findings suggest that IKBKE is a key molecule related to tobacco-induced lung cancer.

"Since IKBKE kinase is induced by tobacco, small molecular inhibitors of IKBKE could have a potential for lung cancer," explained lead author Jin Q. Cheng, Ph.D., M.D., senior member of the Molecular Oncology Department at Moffitt.

Current treatments for non-small cell lung cancer include surgery, radiotherapy and chemotherapy. However, patients eventually develop resistance to treatment. There is a great need to better understand the molecular mechanism of resistance and develop new gene-targeted therapies that can circumvent resistance, said the authors.

In this study, the researchers also reported for the first time that IKBKE is a target of STAT3, a transcription factor that plays a key role in many cellular processes, such as cell growth and programmed cell death.

According to the researchers, STAT3 is frequently activated in various types of human cancers and, when activated, STAT3 increases IKBKE overexpression and protein levels. In non-small cell lung cancer, nicotine-induced IKBKE depends on STAT3.

The authors noted that the activation stage of STAT3 represents an attractive therapeutic potential because IKBKE is a STAT3 target. While IKBKE induces chemotherapy resistance, knocking down IKBKE sensitizes cancer cells to chemotherapy and reduces cancer cell survival.

"Since the IKBKE kinase overexpression is induced by tobacco smoke and IKBKE levels increase in response to nicotine and nicotine-derived nitrosamine ketone, this evidence can be potentially used to develop a non-small cell lung cancer intervention strategy that targets IKBKE," concluded Cheng.

More information: www.nature.com/onc/journal/v32… 2/pdf/onc201239a.pdf

Related Stories

Researchers find more clues to causes of breast cancer

Oct 27, 2011

Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component ...

Nicotine does not promote lung cancer growth in mouse models

Apr 04, 2011

Nicotine at doses similar to those found in most nicotine replacements therapies did not increase lung cancer tumor incidence, frequency or size, according to results of a mouse study presented at the AACR 102nd Annual Meeting ...

Recommended for you

New paper describes how DNA avoids damage from UV light

10 hours ago

In the same week that the U.S. surgeon general issued a 101-page report about the dangers of skin cancer, researchers at Montana State University published a paper breaking new ground on how DNA – the genetic code in every ...

Drug target identified for common childhood blood cancer

12 hours ago

In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers at NYU Langone Medical Center report that they have identified ...

User comments